Business
Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization
Bayer and Cradle today announced that they have entered a three-year strategic collaboration to deploy Cradle's scientific AI software platform for protein engineering. As part of the collaboration, Bayer will integrate the generative AI platform into existing R&D workflows to enhance lead generation and optimization across its therapeutic antibody pipeline.
About this update from Bayer Ag
[{"type":"list","items":[{"val":[{"type":"text","content":"Cradle provides a scientific AI software platform focused on protein engineering","length":80,"tagName":"p"}]},{"val":[{"type":"text","content":"Bayer continues to utilize AI in R&D, reinforcing commitment to modernize and scale its drug discovery and development efforts","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"Bayer and Cradle to jointly work on a machine learning research project to further develop capabilities","length":103,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":313,"olType":false},{"type":"text","content":"BERLIN and AMSTERDAM and ZURICH, Jan. 7, 2026 /PRNewswire/ -- Bayer and Cradle today announced that they have entered a three-year strategic collaboration to deploy Cradle's scientific AI software platform for protein engineering. As part of the collaboration, Bayer will integrate the generative AI platform into existing R&D workflows to enhance lead generation and optimization across its therapeutic antibody pipeline.","length":430,"tagName":"p"},{"type":"image","alt":"Bayer","displaySize":"","headline":null,"caption":"Bayer","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/2bac2d353ed2354fb2a323263f922556"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZXTQmJeE_gAuvHNkCcZxKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2bac2d353ed2354fb2a323263f922556","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2855877/Cradle_Bayer_Collaborate.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Bayer selected Cradle's platform to bring higher-quality molecules into clinical development faster by reducing the number of optimization cycles, improving molecular potency, safety and manufacturability, and increasing probability of technical success as Bayer expands to more demanding modes of action.","length":309,"tagName":"p"},{"type":"text","content":""We believe AI-driven molecule design, discovery and optimization will be a key accelerator of our productivity moving forward," said Anastasia Hager, Ph.D., Global Head of Drug Discovery Sciences at Bayer's Pharmaceuticals Division. "Cradle's platform provides us with scalable scientist-centric ...